In a $5.6 billion dollar market by most estimates, many are seeing the benefit of buying up compounding pharmacies. See what this investor board has to say.

This is a $5.6B market which is not monopolized by any one company. Let's say MAV's revenues realize a loss of 10-30% (just a guess), and SCRC averaged $4M each month. Monthly revenues would now be $2.8M - $3.6M, if SCRC acquires interest in two additional pharmacies generating the same volume, total monthly revenues could top $6M each month. Could you imagine the monthly revenue number if Mr. Schneiderman continues to add pharmacies? 

We have to remember, MAV is not the revenue stream. Compounding pharmacy is. I see future PRs stating "SCRC's monthly revenues for compounding were $6M" versus "MAV reported x-amount of revenues". 
read entire comments here